PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences. Details of the events are as follows:

• Cowen 41st Annual Health Care Conference
  Date: March 4, 2021
  Time: 1:30 pm – 2:30 pm ET
  Chief Executive Officer, Jonathan P. Mow, is scheduled to participate in a panel discussion

• H.C. Wainwright Global Life Sciences Conference
  Date: March 9, 2021
  Time: On demand beginning at 7:00 am ET
  Chief Executive Officer, Jonathan P. Mow, will present a company overview

Interested parties can access the live and archived webcasts of the virtual sessions on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replays will be available for 90 days after the conclusion of the live presentations.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005652/en/

Investor Contact:
John Sharp
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer
(610) 981-6506
[email protected]

Media Contact:
Will Zasadny
Canale Communications, Inc.
[email protected]
(619) 961-8848

Source: PhaseBio Pharmaceuticals, Inc.

You May Also Be Interested In

• Avnet Increases Quarterly Dividend by 5.7%
• Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
• Adeptus Completes Third Acquisition Since Joining Current Platform, Expanding Southern California Advisory Practice